Estrella Immunopharma Inc... (ESLA)
NASDAQ: ESLA
· Real-Time Price · USD
0.94
0.11 (12.68%)
At close: Jun 04, 2025, 3:59 PM
0.95
0.27%
After-hours: Jun 04, 2025, 05:37 PM EDT
Company Description
Estrella Immunopharma, Inc., a preclinical-stage biopharmaceutical company, develops T-cell therapies for blood cancers and solid tumors in the United States.
The company's lead product candidates include EB103 for the treatment of diffuse large B-cell lymphoma and is in pre clinical trial; and EB104 to treat diffuse large B-cell lymphoma and acute lymphocytic leukemia.
It has a collaborative partnership with Imugene Limited for the development of solid tumor treatments using Imugene's product candidate CF33-CD19t in conjunction with EB103.
Estrella Immunopharma, Inc. is based in EmeryVille, California.
Estrella Immunopharma Inc.

Country | United States |
IPO Date | Sep 14, 2021 |
Industry | Biotechnology |
Sector | Healthcare |
Employees | n/a |
CEO | Dr. Cheng Liu Ph.D. |
Contact Details
Address: 5858 Horton Street EmeryVille, California United States | |
Website | https://www.estrellabio.com |
Stock Details
Ticker Symbol | ESLA |
Exchange | NASDAQ |
Fiscal Year | July - June |
Reporting Currency | USD |
CIK Code | 0001844417 |
CUSIP Number | 297584104 |
ISIN Number | US2975841048 |
Employer ID | 00-0000000 |
SIC Code | 6770 |
Key Executives
Name | Position |
---|---|
Dr. Cheng Liu Ph.D. | Chief Executive Officer, President & Director |
Jiandong Xu | Chief Financial Officer |
Latest SEC Filings
Date | Type | Title |
---|---|---|
Jun 03, 2025 | 8-K | Current Report |
May 29, 2025 | 8-K | Current Report |
May 14, 2025 | 10-Q | Quarterly Report |
May 02, 2025 | 8-K | Current Report |
Mar 25, 2025 | 10-KT | Filing |
Feb 21, 2025 | 8-K | Current Report |
Feb 20, 2025 | 8-K | Current Report |
Feb 14, 2025 | 4 | Filing |
Feb 14, 2025 | 4 | Filing |
Dec 23, 2024 | S-8 | Filing |